AA |
Amino acids |
ACMG |
American College of Medical Genetics and Genomics |
AO |
Administrative order (Department of Health—Philippines) |
ASA |
Argininosuccinic aciduria |
BIO |
Biotinidase deficiency |
CAH |
Congenital adrenal hyperplasia |
CDC |
Centers for Disease Control and Prevention (United States) |
CF |
Cystic fibrosis |
CH |
Congenital hypothyroidism |
CHGS |
Center for Human Genetic Services |
CNSP |
California Newborn Screening Program |
COVID-19 |
Coronavirus disease 2019 |
DOH |
Department of Health (Philippines) |
ENBS |
Expanded newborn bloodspot screening |
FAO |
Fatty acid oxidation |
G6PD |
Glucose-6-phosphate dehydrogenase |
GAL |
Galactosemia |
HCY |
Homocystinuria |
HGB |
Hemoglobinopathy |
IHG |
Institute of Human Genetics (Philippines) |
LIMS |
Laboratory information management system |
LMIC |
Low- and middle-income countries |
MS/MS |
Tandem mass spectrometry |
MSUD |
Maple syrup urine disease |
NBS |
Newborn bloodspot screening |
NBSCC |
Newborn Screening Continuity Clinic (long-term follow-up) |
NCNBSS |
National comprehensive newborn screening system |
NIH |
National Institutes of Health (Philippines) |
NNSGRC |
National Newborn Screening and Global Resource Center (U.S.) |
NSC |
Newborn Screening Center (screening laboratory) |
NSF |
Newborn Screening Facility (screening specimen collection site) |
NSQAP |
Newborn Screening Quality Assurance Program (U.S.-CDC) |
NSRC |
Newborn Screening Reference Center (Philippines) |
NTWG |
Newborn Screening Technical Working Group |
OA |
Organic acid |
PHIC |
Philippine Health Insurance Corporation (national health insurance) |
PKU |
Phenylketonuria |
PNSP |
Philippine Newborn Screening Program |
PT |
Proficiency testing |
QA |
Quality assurance |
QC |
Quality control |
RUSP |
Recommended uniform screening panel (U.S.) |